*4.2. HSV-1*

Inhibition of HSV-1 by cationic peptides has been previously reported, including the antimicrobial peptide LL-37 that presumably acts by targeting factors within the viral membrane [54–56]. It is believed that HSV-1 derives its final envelope from membranes of the late secretory pathway (e.g., trans-Golgi network) and/or endosomal pathway [57]. The inhibition of HSV-1 by CPXV012 peptide suggests that PS in the HSV-1 envelope is a potent target for antiviral therapy.
